<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>PCOS – Primary Care Quick Reference</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800&display=swap" rel="stylesheet">
  <style>
    :root {
      --bg: #0b1020;
      --bg-soft: #121832;
      --card: #11162a;
      --text: #e8ecf8;
      --muted: #b7c1df;
      --accent: #7c6cff;
      --accent-2: #00d4ff;
      --ok: #24d17e;
      --warn: #ffd166;
      --danger: #ff7a7a;
      --border: rgba(255,255,255,0.08);
      --shadow: 0 10px 30px rgba(0,0,0,.35);
    }
    
    @media (prefers-color-scheme: light) {
      :root {
        --bg: #f6f8ff;
        --bg-soft: #eef2ff;
        --card: #ffffff;
        --text: #0f172a;
        --muted: #475569;
        --accent: #6d28d9;
        --accent-2: #0891b2;
        --border: rgba(2,6,23,0.08);
        --shadow: 0 6px 20px rgba(2,6,23,.08);
      }
    }

    * { box-sizing: border-box; }
    html, body { height: 100%; }
    body {
      margin: 0;
      font-family: Inter, system-ui, -apple-system, Segoe UI, Roboto, "Helvetica Neue", Arial, "Apple Color Emoji", "Segoe UI Emoji";
      background: radial-gradient(1200px 700px at 10% -10%, rgba(124,108,255,0.15), transparent 50%),
                  radial-gradient(1000px 600px at 110% 10%, rgba(0,212,255,0.15), transparent 40%),
                  var(--bg);
      color: var(--text);
      line-height: 1.5;
    }

    .container { max-width: 1200px; margin: 0 auto; padding: 24px; }

    header.hero {
      position: relative;
      background: linear-gradient(135deg, rgba(124,108,255,.2), rgba(0,212,255,.2));
      border: 1px solid var(--border);
      border-radius: 20px;
      padding: 24px 24px 18px;
      box-shadow: var(--shadow);
      overflow: hidden;
    }

    .hero h1 {
      margin: 0 0 6px;
      font-weight: 800;
      letter-spacing: -0.02em;
      font-size: clamp(22px, 3vw, 36px);
    }
    .sub {
      margin: 0; opacity: .85; color: var(--muted);
      font-size: clamp(13px, 2vw, 16px);
    }

    .controls { display: flex; gap: 12px; align-items: center; flex-wrap: wrap; margin-top: 16px; }
    .btn {
      appearance: none; border: 1px solid var(--border); background: var(--card); color: var(--text);
      padding: 10px 14px; border-radius: 12px; font-weight: 600; cursor: pointer; box-shadow: var(--shadow);
      display: inline-flex; align-items: center; gap: 8px; transition: transform .06s ease, background .2s ease;
    }
    .btn:hover { transform: translateY(-1px); }
    .btn .icon { width: 18px; height: 18px; }

    .search {
      flex: 1 1 260px; display: flex; align-items: center; gap: 8px; background: var(--card);
      border: 1px solid var(--border); border-radius: 12px; padding: 8px 12px; box-shadow: var(--shadow);
    }
    .search input {
      flex: 1; border: 0; outline: 0; background: transparent; color: var(--text); font-size: 14px;
    }

    .grid {
      margin-top: 24px;
      display: grid; grid-template-columns: 1.7fr 1fr; gap: 20px;
    }
    @media (max-width: 960px) { .grid { grid-template-columns: 1fr; } }

    .card {
      background: var(--card); border: 1px solid var(--border); border-radius: 18px; padding: 18px 18px; box-shadow: var(--shadow);
    }

    .section-title { display: flex; align-items: center; gap: 10px; margin: 4px 0 12px; }
    .pill-num { width: 28px; height: 28px; border-radius: 50%; display: grid; place-items: center; font-weight: 800; font-size: 14px; color: #fff; background: linear-gradient(135deg, var(--accent), var(--accent-2)); }
    .section-title h2 { margin: 0; font-size: 18px; letter-spacing: .2px; }

    .hint { color: var(--muted); font-size: 13px; }

    ul { margin: 8px 0 0 0; padding-left: 20px; }
    li { margin: 6px 0; }

    .two-col {
      display: grid; grid-template-columns: 1fr 1fr; gap: 14px;
    }
    @media (max-width: 720px) { .two-col { grid-template-columns: 1fr; } }

    .badge { display: inline-block; font-size: 12px; padding: 4px 8px; border-radius: 999px; background: rgba(124,108,255,.12); border: 1px solid var(--border); margin-right: 6px; }

    .callout {
      border-left: 4px solid var(--accent); padding: 10px 12px; background: linear-gradient(180deg, rgba(124,108,255,.08), transparent);
      border-radius: 10px; margin-top: 8px; font-size: 14px;
    }

    .keypoint { background: linear-gradient(135deg, rgba(36,209,126,.12), rgba(0,212,255,.08)); border-left-color: var(--ok); }

    .metrics { display: grid; grid-template-columns: repeat(3, 1fr); gap: 10px; }
    @media (max-width: 960px) { .metrics { grid-template-columns: 1fr 1fr; } }
    @media (max-width: 520px) { .metrics { grid-template-columns: 1fr; } }

    .metric {
      background: linear-gradient(180deg, rgba(255,255,255,0.02), rgba(0,0,0,0.03)); border: 1px solid var(--border);
      border-radius: 14px; padding: 12px; display: grid; gap: 4px;
    }
    .metric h3 { margin: 0; font-size: 12px; color: var(--muted); font-weight: 600; }
    .metric .value { font-weight: 800; font-size: 22px; letter-spacing: -0.02em; }
    .metric small { color: var(--muted); }

    table { width: 100%; border-collapse: collapse; font-size: 14px; }
    th, td { border-bottom: 1px dashed var(--border); padding: 8px 6px; text-align: left; }
    th { font-size: 12px; text-transform: uppercase; letter-spacing: .04em; color: var(--muted); }

    .sticky { position: sticky; top: 16px; }

    footer { margin: 16px 0 40px; color: var(--muted); font-size: 12px; text-align: center; }

    /* Print: compress for one-page A4 */
    @media print {
      @page { size: A4; margin: 9mm; }
      body { background: #fff; color: #000; }
      .hero, .card { box-shadow: none; }
      .controls { display: none !important; }
      .container { padding: 0; }
      .grid { gap: 10px; }
      .section-title h2 { font-size: 15px; }
      body, .card, ul, li, table { font-size: 11px; }
      .metric .value { font-size: 16px; }
    }
  </style>
</head>
<body>
  <div class="container">
    <header class="hero">
      <h1>PCOS – Primary Care Quick Reference Algorithm</h1>
      <p class="sub">Fast decision aide for consultations • Adapted from NICE CKS (last revised March 2025). For clinical use alongside full guidance.</p>

      <div class="controls">
        <div class="search" role="search" aria-label="Filter content">
          <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><circle cx="11" cy="11" r="8"></circle><line x1="21" y1="21" x2="16.65" y2="16.65"></line></svg>
          <input id="filter" placeholder="Type to filter (e.g. ‘OGTT’, ‘adolescents’, ‘hirsutism’)" />
        </div>
        <button class="btn" onclick="toggleTheme()" aria-label="Toggle theme">
          <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"/></svg>
          Theme
        </button>
        <button class="btn" onclick="window.print()" aria-label="Print this page">
          <svg class="icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><polyline points="6 9 6 2 18 2 18 9"/><path d="M6 18H4a2 2 0 0 1-2-2v-5a2 2 0 0 1 2-2h16a2 2 0 0 1 2 2v5a2 2 0 0 1-2 2h-2"/><rect x="6" y="14" width="12" height="8"/></svg>
          Print
        </button>
      </div>
    </header>

    <div class="grid">
      <!-- MAIN COLUMN -->
      <main class="stack" id="content">
        <section class="card" data-section="suspect adults adolescents diagnosis features irregular cycles acanthosis family obesity">
          <div class="section-title"><div class="pill-num">1</div><h2>Suspect PCOS</h2></div>
          <div class="two-col">
            <div>
              <strong>Adults</strong>
              <ul>
                <li>Hyperandrogenism: hirsutism, acne, female pattern hair loss.</li>
                <li>Ovulatory dysfunction: oligo-/amenorrhoea, infertility.</li>
                <li>Consider: family history, central obesity/insulin resistance, <em>acanthosis nigricans</em>.</li>
              </ul>
            </div>
            <div>
              <strong>Adolescents</strong>
              <ul>
                <li><u>Require BOTH</u> clinical hyperandrogenism <em>and</em> irregular cycles (definitions below).</li>
                <li>Those with features but not meeting criteria: label “increased risk”; reassess ≤ 8 yrs post‑menarche.</li>
              </ul>
            </div>
          </div>
          <div class="callout hint">Irregular cycles (post‑menarche definitions): 1–&lt;3 yrs: &gt;45 d or &lt;21 d; ≥3 yrs: &gt;35 d or &lt;21 d or &lt;8/yr; any cycle &gt;90 d ≥1 yr post‑menarche; primary amenorrhoea by 15 yrs or >3 yrs post‑thelarche.</div>
        </section>

        <section class="card" data-section="investigations labs testosterone shbg fai androstenedione dheas tsh prolactin fsh lh ultrasound follicles contraception withdraw 3 months">
          <div class="section-title"><div class="pill-num">2</div><h2>Investigations</h2></div>
          <div class="two-col">
            <div>
              <strong>Hormonal</strong>
              <ul>
                <li>Total testosterone ± <abbr title="Free Androgen Index">FAI</abbr> (↑/normal); SHBG (normal/↓).</li>
                <li>If T/FAI not elevated → consider androstenedione &amp; DHEAS.</li>
              </ul>
              <div class="callout">On hormonal contraception? Reliable biochemical hyperandrogenism assessment isn’t possible.
                If essential, <b>stop COC for ≥3 months</b> and ensure alternative contraception.</div>
            </div>
            <div>
              <strong>Exclude differentials</strong>
              <ul>
                <li>TSH, prolactin, FSH/LH; consider non‑classic CAH, Cushing’s, androgen‑secreting tumour (rapid virilisation, T &gt;5 nmol/L).</li>
                <li><b>Ultrasound (adults):</b> polycystic morphology = <b>≥20 follicles</b> in ≥1 ovary. <span class="badge">Not for adolescents</span></li>
              </ul>
            </div>
          </div>
          <div class="callout hint">Baseline metabolic/CVD screen at diagnosis: OGTT or HbA1c (± fasting glucose), lipids, BP, BMI &amp; waist.</div>
        </section>

        <section class="card" data-section="diagnosis criteria rotterdam hyperandrogenism ovulatory dysfunction polycystic ovarian morphology ethnicity postmenopause enduring">
          <div class="section-title"><div class="pill-num">3</div><h2>Diagnosis</h2></div>
          <ul>
            <li><b>Adults:</b> Any <u>2 of 3</u>: (1) clinical/biochemical hyperandrogenism; (2) ovulatory dysfunction; (3) polycystic ovarian morphology on USS.</li>
            <li><b>Adolescents:</b> <u>Both</u> hyperandrogenism + irregular cycles required (no USS).</li>
            <li>Note ethnic variation in presentation/thresholds; use clinical judgement.</li>
            <li>PCOS is <em>enduring</em>; hyperandrogenism may persist post‑menopause. Consider alternate causes if late/severe onset.</li>
          </ul>
        </section>

        <section class="card" data-section="management lifestyle cycle endometrium hirsutism acne metformin contraception progestogen LNG IUD ultrasound surveillance">
          <div class="section-title"><div class="pill-num">4</div><h2>Management</h2></div>
          <div class="two-col">
            <div>
              <strong>Lifestyle – first line</strong>
              <ul>
                <li>Weight optimisation, healthy diet, regular physical activity.</li>
                <li>Benefits: improved cycles/fertility, ↓ insulin resistance, ↓ CVD risk, QoL ↑.</li>
              </ul>
              <strong>Cycle / Endometrium</strong>
              <ul>
                <li><b>COC</b> first line if no contraindications. <span class="badge">Avoid EE 35 µg + cyproterone as 1st line</span></li>
                <li><b>Prolonged amenorrhoea (&gt;3 mo) or AUB:</b> induce bleed with cyclical progestogen (e.g., medroxyprogesterone 10 mg × 14 d) → USS endometrium.</li>
                <li>If endometrium <b>&gt;10 mm</b> or atypical → refer for sampling.</li>
                <li>Prevention options: cyclical progestogen q1–3 mo, low‑dose COC, or <b>LNG‑IUD</b>.</li>
                <li>Declines hormones/IUD → seek specialist advice; consider 6–12 mo USS surveillance.</li>
              </ul>
            </div>
            <div>
              <strong>Hyperandrogenism</strong>
              <ul>
                <li>Acne: COC ± dermatology agents per acne severity.</li>
                <li>Hirsutism: COC; discuss hair‑removal methods (will remain important).</li>
              </ul>
              <strong>Metformin <span class="badge">off‑label</span></strong>
              <ul>
                <li>Consider if BMI ≥25, diabetes risk factors, insulin resistance, high‑risk ethnicity, or metabolic goals unmet with COC/lifestyle.</li>
                <li>Counsel on GI effects &amp; possible ↓B12; review ongoing need.</li>
              </ul>
            </div>
          </div>
          <div class="callout keypoint"><b>Pregnancy:</b> If pregnant/planning, offer OGTT pre‑conception or &lt;20 weeks; all with PCOS: OGTT at 24–28 weeks. Review/stop hormonal treatments when pregnant.</div>
        </section>

        <section class="card" data-section="screening risk reduction metabolic ogtt lipids blood pressure qrisk3 osas depression anxiety eating disorders nafld">
          <div class="section-title"><div class="pill-num">5</div><h2>Screening &amp; Risk Reduction</h2></div>
          <div class="two-col">
            <div>
              <ul>
                <li><b>Glycaemic status:</b> baseline for all; repeat q1–3 yrs. In high‑risk (BMI ≥25; Asians ≥23; HTN; age &gt;40; GDM/IFG/IGT; non‑Caucasian): prefer <b>OGTT</b>; annual OGTT if IFG/IGT.</li>
                <li><b>Lipids:</b> fasting profile at diagnosis; repeat per CVD risk/treatment.</li>
                <li><b>BP:</b> at least annually (more often per global CVD risk).</li>
                <li><b>Smoking:</b> assess &amp; support cessation.</li>
              </ul>
            </div>
            <div>
              <ul>
                <li><b>CVD risk:</b> consider QRISK3 (use cautiously; not validated specifically for PCOS).</li>
                <li><b>OSAS:</b> ask about snoring, daytime sleepiness; screen if symptomatic (e.g., STOP‑Bang, Epworth; don’t use Epworth alone for referral).</li>
                <li><b>Psychological:</b> screen for depression, anxiety, eating disorders; address body‑image/psychosexual issues.</li>
                <li><b>NAFLD:</b> consider risk and manage per NAFLD guidance.</li>
              </ul>
            </div>
          </div>
        </section>

        <section class="card" data-section="referral infertility endometrial thickening abnormal bleeding virilisation testosterone 5 nmol tumour adolescent complex">
          <div class="section-title"><div class="pill-num">6</div><h2>Refer / Seek Specialist Advice</h2></div>
          <ul>
            <li>Infertility management or pre‑conception optimisation.</li>
            <li>Endometrial thickness &gt;10 mm, atypical appearance, or abnormal bleeding.</li>
            <li>Severe/rapid virilisation or <b>total testosterone &gt;5 nmol/L</b> (or &gt;2× ULN): rule out androgen‑secreting tumour.</li>
            <li>Uncertain/complex adolescent presentation or when declining standard endometrial protection.</li>
          </ul>
        </section>

        <section class="card" data-section="key point lifelong goals symptoms metabolic cvd psychological fertility">
          <div class="section-title"><div class="pill-num">✔</div><h2>Key Point</h2></div>
          <div class="callout keypoint">PCOS is lifelong. Goals: control symptoms (cycles, acne, hirsutism), prevent metabolic/CVD/psychological complications, and support fertility goals.</div>
        </section>
      </main>

      <!-- SIDEBAR -->
      <aside class="sticky" aria-label="Quick thresholds and tables">
        <section class="card">
          <div class="section-title"><div class="pill-num">★</div><h2>Quick Thresholds</h2></div>
          <div class="metrics">
            <div class="metric"><h3>USS follicles</h3><div class="value">≥ 20</div><small>in ≥1 ovary = polycystic morphology (adults)</small></div>
            <div class="metric"><h3>Endometrium</h3><div class="value">&gt; 10 mm</div><small>or atypical → sample</small></div>
            <div class="metric"><h3>Total testosterone</h3><div class="value">&gt; 5 nmol/L</div><small>or &gt;2× ULN → urgent evaluation</small></div>
            <div class="metric"><h3>COC hormones</h3><div class="value">≥ 3 mo off</div><small>before androgen testing if essential</small></div>
            <div class="metric"><h3>Glycaemia</h3><div class="value">q1–3 yrs</div><small>OGTT preferred in high‑risk</small></div>
            <div class="metric"><h3>USS follow‑up</h3><div class="value">6–12 mo</div><small>if declining endometrial protection</small></div>
          </div>
        </section>

        <section class="card">
          <div class="section-title"><div class="pill-num">ⓘ</div><h2>Adolescent cycle definitions</h2></div>
          <table>
            <thead><tr><th>Stage</th><th>Irregularity</th></tr></thead>
            <tbody>
              <tr><td>1st year post‑menarche</td><td>Irregular common (physiological)</td></tr>
              <tr><td>1–&lt;3 yrs</td><td>&gt;45 d or &lt;21 d</td></tr>
              <tr><td>≥3 yrs to perimenopause</td><td>&gt;35 d or &lt;21 d, or &lt;8 cycles/yr</td></tr>
              <tr><td>≥1 yr post‑menarche</td><td>Any cycle &gt;90 d</td></tr>
              <tr><td>Primary amenorrhoea</td><td>By age 15 yrs or &gt;3 yrs post‑thelarche</td></tr>
            </tbody>
          </table>
        </section>

        <section class="card">
          <div class="section-title"><div class="pill-num">☑</div><h2>Handy Tools</h2></div>
          <ul>
            <li>OSAS screening: STOP‑Bang, Epworth (not alone for referral).</li>
            <li>CVD: QRISK3 (interpret cautiously in PCOS).</li>
            <li>Lifestyle: weight, BMI, waist at each visit; support cessation.</li>
          </ul>
        </section>
      </aside>
    </div>

    <footer>
      © This quick reference is an aide‑memoire for clinicians and does not replace full guidance. Adapted from NICE CKS: Polycystic ovary syndrome (Mar 2025).
    </footer>
  </div>

  <script>
    // Theme toggle with localStorage
    const prefersDark = window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches;
    const savedTheme = localStorage.getItem('theme');
    if (savedTheme === 'dark' || (!savedTheme && prefersDark)) document.body.classList.add('dark');

    function toggleTheme(){
      document.body.classList.toggle('dark');
      localStorage.setItem('theme', document.body.classList.contains('dark') ? 'dark' : 'light');
    }

    // Simple filter: hides cards that don't include the term
    const filterInput = document.getElementById('filter');
    const sections = Array.from(document.querySelectorAll('[data-section]'));
    filterInput.addEventListener('input', (e) => {
      const q = e.target.value.trim().toLowerCase();
      sections.forEach(sec => {
        const hay = (sec.innerText + ' ' + (sec.getAttribute('data-section')||'')).toLowerCase();
        sec.style.display = q && !hay.includes(q) ? 'none' : '';
      });
    });
  </script>
</body>
</html>